Physician profile
Bo Wang
NPI 1619357365
$251,417.07
in general payments reported to CMS, 2019-2025
41 companies · $84K in 2025
The $84K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,942 · 2020: $5,958 · 2021: $9,527 · 2022: $43K · 2023: $56K · 2024: $47K · 2025: $84K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $105K · Consulting Fee: $57K · Travel and Lodging: $11K · Food and Beverage: $9,902 · Honoraria: $4,550 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $104,865.50 |
| Consulting Fee | $56,568.25 |
| Travel and Lodging | $11,380.34 |
| Food and Beverage | $9,901.70 |
| Honoraria | $4,550.00 |
| Education | $126.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $70,951.12 | 2019-2025 | Tagrisso, Datroway, Imfinzi |
| Emd Serono, INC. | $54,415.12 | 2022-2024 | Bavencio, Tepmetko |
| Genzyme Corporation | $36,937.15 | 2019-2025 | |
| Amgen INC. | $16,445.13 | 2019-2025 | Imdelltra (Amg757), Lumakras, Vectibix |
| Daiichi Sankyo INC. | $13,792.48 | 2024-2025 | Datroway, Enhertu |
| Genentech USA, INC. | $9,864.55 | 2019-2025 | |
| Novocure INC. | $6,348.84 | 2023-2025 | Optune Lua (Novottf-200t) |
| Karyopharm Therapeutics INC. | $5,743.35 | 2022-2023 | Xpovio |
| Abbvie INC. | $5,520.26 | 2023-2025 | Venclexta |
| Lilly USA, LLC | $4,768.24 | 2023 | Retevmo |
| Regeneron Pharmaceuticals, INC. | $4,321.41 | 2023-2025 | Libtayo |
| Pfizer INC. | $4,267.70 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $3,333.51 | 2019-2025 | Krazati, Opdivo |
| Array Biopharma INC | $2,520.00 | 2022 | |
| Janssen Scientific Affairs, LLC | $1,742.61 | 2022-2025 | Erleada, Imbruvica, Rybrevant |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim International Gmbh | $1,720.00 | 2025 | |
| Beigene USA, INC. | $1,625.00 | 2024 | Tevimbra |
| Partner Therapeutics, INC. | $1,000.00 | 2025 | Bizengri |
| Takeda Pharmaceuticals U.S.A., INC. | $891.21 | 2019-2025 | Exkivity |
| Genentech, INC. | $874.79 | 2022-2025 | Tecentriq, Lunsumio, Columvi |
| Eli Lilly and Company | $800.00 | 2024 | Retevmo |
| Gilead Sciences, INC. | $589.25 | 2023-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $445.98 | 2022-2025 | Keytruda |
| Glaxosmithkline, LLC. | $425.00 | 2021-2022 | |
| Seagen INC. | $339.44 | 2020-2023 | |
| Jazz Pharmaceuticals INC. | $285.09 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $250.00 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $244.44 | 2019-2020 | |
| Foundation Medicine, INC. | $184.88 | 2022-2023 | |
| Reflexion Medical, INC. | $156.00 | 2024 | Reflexion Medical Radiotherapy System |
| Celgene Corporation | $135.30 | 2023 | Reblozyl |
| Janssen Biotech, INC. | $102.49 | 2024-2025 | Rybrevant |
| Alexion Pharmaceuticals, INC. | $99.99 | 2019 | |
| W. L. Gore & Associates, INC. | $90.58 | 2019 | |
| Sanofi-Aventis U.S. LLC | $89.99 | 2025 | |
| Aveo Pharmaceuticals, INC. | $81.49 | 2022 | |
| Astellas Pharma US INC | $14.68 | 2024 | Xospata |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bo Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.